{"id":"NCT03345836","sponsor":"AbbVie","briefTitle":"A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Biologic Therapy","officialTitle":"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Biologic Therapy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-11-29","primaryCompletion":"2021-08-11","completion":"2021-08-11","firstPosted":"2017-11-17","resultsPosted":"2022-08-15","lastUpdate":"2022-08-15"},"enrollment":624,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Crohn's Disease"],"interventions":[{"type":"DRUG","name":"Matching Placebo for Upadacitinib","otherNames":[]},{"type":"DRUG","name":"Upadacitinib","otherNames":["ABT-494","RINVOQ®"]}],"arms":[{"label":"Part 1 (Double-blind): Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Part 1 (Double-blind): Upadacitinib 45 mg","type":"EXPERIMENTAL"},{"label":"Part 2 (Open-label): Upadacitinib 45 mg","type":"EXPERIMENTAL"},{"label":"Part 3 (Extended Treatment DB): Upadacitinib 45 mg From Part 1 DB Placebo","type":"EXPERIMENTAL"},{"label":"Part 3 (Extended Treatment DB): Upadacitinib 30 mg From Part 1 DB Upadacitinib 45 mg","type":"EXPERIMENTAL"},{"label":"Part 3 (Extended Treatment OL): Upadacitinib 30 mg From Part 2 OL Upadacitinib 45 mg","type":"EXPERIMENTAL"}],"summary":"The objective of this study is to evaluate the efficacy and safety of upadacitinib compared to placebo as induction therapy in participants with moderately and severely active Crohn's disease (CD).","primaryOutcome":{"measure":"Percentage of Participants With Clinical Remission Per Crohn's Disease Activity Index (CDAI) at Week 12","timeFrame":"Week 12","effectByArm":[{"arm":"Part 1 (Double Blind): Placebo","deltaMin":21.1,"sd":null},{"arm":"Part 1 (Double Blind): Upadacitinib 45 mg","deltaMin":38.9,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":6},"locations":{"siteCount":428,"countries":["United States","Argentina","Australia","Austria","Belgium","Bosnia and Herzegovina","Brazil","Bulgaria","Canada","Chile","China","Colombia","Croatia","Czechia","Denmark","Egypt","Estonia","France","Germany","Greece","Hong Kong","Hungary","Ireland","Israel","Italy","Japan","Latvia","Lithuania","Malaysia","Mexico","Netherlands","Poland","Portugal","Puerto Rico","Romania","Russia","Serbia","Singapore","Slovakia","Slovenia","South Africa","South Korea","Spain","Sweden","Switzerland","Taiwan","Turkey (Türkiye)","United Kingdom"]},"refs":{"pmids":["39326583","39231444","38492904","38492903","37224198"],"seeAlso":["http://rxabbvie.com"]},"adverseEventsSummary":{"seriousAny":{"events":17,"n":171},"commonTop":["ACNE","CROHN'S DISEASE","HEADACHE","ANAEMIA","NASOPHARYNGITIS"]}}